Searching for synthetic lethality in cancer.

The incentive to develop personalised therapy for cancer treatment is driven by the premise that it will increase therapeutic efficacy and reduce toxicity. Understanding the underlying cellular and molecular basis of the disease has been extremely important in the design of these novel therapies; however, identifying new drug targets for personalised therapies remains problematic. This review describes how the biological concept of synthetic lethality has been successfully implemented to identify new therapeutic approaches and targets in models from yeast through to human cells. We also discuss how recent technical advances combined with an increased understanding of the complexity of cellular networks may facilitate therapeutic advances in the future.

[1]  Yiyu Dong,et al.  Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. , 2010, Cancer research.

[2]  L. Staudt,et al.  Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells , 2010, Oncogene.

[3]  Gary D Bader,et al.  Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants , 2001, Science.

[4]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[5]  B. Garvik,et al.  Principles for the buffering of genetic variation. , 2001 .

[6]  Ronald W. Davis,et al.  Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. , 1999, Science.

[7]  Nir Hacohen,et al.  Minimizing the risk of reporting false positives in large-scale RNAi screens , 2006, Nature Methods.

[8]  A. Ashworth,et al.  A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. , 2008, DNA repair.

[9]  A. Ashworth,et al.  DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1 , 2010, Cancer cell.

[10]  Rafael A Irizarry,et al.  Global synthetic-lethality analysis and yeast functional profiling. , 2006, Trends in genetics : TIG.

[11]  L. Hartwell,et al.  Differential toxicities of anticancer agents among DNA repair and checkpoint mutants of Saccharomyces cerevisiae. , 2000, Cancer research.

[12]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[13]  A. Ashworth,et al.  Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. , 2008, Cancer cell.

[14]  J. Boeke,et al.  DNA helicase gene interaction network defined using synthetic lethality analyzed by microarray , 2003, Nature Genetics.

[15]  A. Sturtevant,et al.  A Highly Specific Complementary Lethal System in Drosophila Melanogaster. , 1956, Genetics.

[16]  A. Ashworth,et al.  Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 , 2009, EMBO molecular medicine.

[17]  William A Weiss,et al.  Recognizing and exploiting differences between RNAi and small-molecule inhibitors. , 2007, Nature chemical biology.

[18]  Elizabeth Iorns,et al.  Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets , 2009, PloS one.

[19]  Sridhar Ramaswamy,et al.  Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.

[20]  Nevan J Krogan,et al.  High-throughput genetic interaction mapping in the fission yeast Schizosaccharomyces pombe , 2007, Nature Methods.

[21]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[22]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[23]  René Bernards,et al.  shRNA libraries and their use in cancer genetics , 2006, Nature Methods.

[24]  A. Fraser,et al.  Systematic mapping of genetic interactions in Caenorhabditis elegans identifies common modifiers of diverse signaling pathways , 2006, Nature Genetics.

[25]  J. Lucchesi.  Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. , 1968, Genetics.

[26]  T. Dobzhansky,et al.  Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila Pseudoobscura. , 1946, Genetics.

[27]  Y. Dong,et al.  Systematic functional analysis of the Caenorhabditis elegans genome using RNAi , 2003, Nature.

[28]  Alan Ashworth,et al.  A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Elizabeth Iorns,et al.  A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor , 2008, The EMBO journal.

[30]  Ricky A. Sharma,et al.  Molecular and Cellular Pathobiology Cancer Research Poly ( ADP-Ribose ) Polymerase Is Hyperactivated in Homologous Recombination – Defective Cells , 2010 .

[31]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[32]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[33]  Brian D. Peyser,et al.  Gene function prediction from congruent synthetic lethal interactions in yeast , 2005, Molecular systems biology.

[34]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[35]  Y. Oron,et al.  Genetic synthetic lethality screen at the single gene level in cultured human cells. , 2001, Nucleic acids research.

[36]  A. Ashworth,et al.  Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.

[37]  A. Ashworth,et al.  Biology-driven cancer drug development: back to the future , 2010, BMC Biology.

[38]  S. Haggarty,et al.  High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. , 1999, Chemistry & biology.

[39]  Joshua M. Stuart,et al.  A global analysis of genetic interactions in Caenorhabditis elegans , 2007, Journal of biology.

[40]  Sean R. Collins,et al.  A tool-kit for high-throughput, quantitative analyses of genetic interactions in E. coli , 2008, Nature Methods.

[41]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[42]  S. Wright.  DOBZHANSKY'S GENETICS OF NATURAL POPULATIONS , 1982 .

[43]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[44]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[45]  Elizabeth Iorns,et al.  Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. , 2009, The Biochemical journal.

[46]  Ronald W. Davis,et al.  Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.

[47]  L. Hartwell,et al.  Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.

[48]  Gary D Bader,et al.  Global Mapping of the Yeast Genetic Interaction Network , 2004, Science.